{"id":"daratumumab-rhuph20","safety":{"commonSideEffects":[{"rate":null,"effect":"Infusion reactions"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL1743007","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Daratumumab binds to CD38, a surface antigen highly expressed on multiple myeloma cells, triggering immune-mediated cell death through antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antibody-dependent cellular phagocytosis (ADCP). The rHuPH20 enzyme facilitates rapid subcutaneous absorption by temporarily degrading hyaluronic acid in subcutaneous tissue, allowing for faster and more complete drug delivery compared to standard subcutaneous administration.","oneSentence":"Daratumumab is a monoclonal antibody that targets CD38 on multiple myeloma cells, while rHuPH20 is a recombinant human hyaluronidase that enhances subcutaneous delivery by breaking down hyaluronic acid in the extracellular matrix.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:08:37.922Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma (subcutaneous formulation in phase 3 development)"}]},"trialDetails":[{"nctId":"NCT06169215","phase":"PHASE2","title":"Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-07-23","conditions":"Multiple Myeloma","enrollment":70},{"nctId":"NCT06948084","phase":"PHASE2","title":"Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-29","conditions":"Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":80},{"nctId":"NCT07485647","phase":"PHASE2","title":"Identifying Effective and Cost-Conscious Maintenance Daratumumab Dosing","status":"NOT_YET_RECRUITING","sponsor":"Eden Biltibo","startDate":"2026-05","conditions":"Multiple Myeloma","enrollment":50},{"nctId":"NCT03301220","phase":"PHASE3","title":"A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2017-11-07","conditions":"Smoldering Multiple Myeloma","enrollment":390},{"nctId":"NCT04566328","phase":"PHASE3","title":"Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2021-02-24","conditions":"Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell Myeloma","enrollment":1450},{"nctId":"NCT07082270","phase":"PHASE1","title":"Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2026-04-01","conditions":"Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":21},{"nctId":"NCT05511428","phase":"PHASE4","title":"Home Based Daratumumab Administration for Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Thomas Jefferson University","startDate":"2022-11-08","conditions":"Plasma Cell Myeloma","enrollment":20},{"nctId":"NCT04070378","phase":"PHASE2","title":"Study of Daratumumab in Patients With Mild to Moderate Alzheimer's Disease","status":"COMPLETED","sponsor":"Marc L Gordon, MD","startDate":"2019-11-06","conditions":"Alzheimer Disease","enrollment":16},{"nctId":"NCT03837509","phase":"PHASE1, PHASE2","title":"INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma","status":"TERMINATED","sponsor":"Incyte Corporation","startDate":"2019-09-25","conditions":"Relapsed or Refractory Multiple Myeloma","enrollment":15},{"nctId":"NCT06046287","phase":"PHASE2","title":"Daratumumab for Polyneuropathy Associated With MGUS","status":"WITHDRAWN","sponsor":"Georgetown University","startDate":"2025-09-26","conditions":"Peripheral Neuropathy, Monoclonal Gammopathy of Undetermined Significance","enrollment":""},{"nctId":"NCT06022939","phase":"PHASE3","title":"Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2024-07-01","conditions":"AL Amyloidosis","enrollment":338},{"nctId":"NCT04071457","phase":"PHASE3","title":"S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration","status":"ACTIVE_NOT_RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2019-08-13","conditions":"Multiple Myeloma","enrollment":1100},{"nctId":"NCT05561387","phase":"PHASE3","title":"Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2023-10-12","conditions":"Plasma Cell Myeloma","enrollment":510},{"nctId":"NCT02519452","phase":"PHASE1","title":"A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-10-22","conditions":"Multiple Myeloma","enrollment":120},{"nctId":"NCT03277105","phase":"PHASE3","title":"A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-10-27","conditions":"Multiple Myeloma","enrollment":522},{"nctId":"NCT04131309","phase":"PHASE2","title":"A Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) Amyloidosis","status":"COMPLETED","sponsor":"Stichting European Myeloma Network","startDate":"2019-09-23","conditions":"Light Chain (AL) Amyloidosis, Stage 3B","enrollment":40},{"nctId":"NCT06622005","phase":"PHASE1","title":"SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2025-04-10","conditions":"Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":15},{"nctId":"NCT03320707","phase":"PHASE1","title":"A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-54767414 (Daratumumab) in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-10-16","conditions":"Healthy","enrollment":66},{"nctId":"NCT06107738","phase":"PHASE2","title":"Iberdomide and Daratumumab As Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma","status":"RECRUITING","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2023-12-21","conditions":"Multiple Myeloma","enrollment":60},{"nctId":"NCT04714372","phase":"PHASE1","title":"FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2021-11-03","conditions":"Acute Myeloid Leukemia, Myeloid Leukemia, Monocytic Leukemia","enrollment":9},{"nctId":"NCT04956302","phase":"PHASE1","title":"Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma","status":"TERMINATED","sponsor":"Abdullah Khan","startDate":"2021-09-27","conditions":"Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma","enrollment":1},{"nctId":"NCT04121260","phase":"PHASE1","title":"A Study of Subcutaneous Delivery of JNJ-54767414 in Chinese Participants With Multiple Myeloma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-12-25","conditions":"Multiple Myeloma","enrollment":21},{"nctId":"NCT03242889","phase":"PHASE1","title":"A Study of Subcutaneous Delivery of JNJ-54767414 (Daratumumab) in Japanese Participants With Relapsed or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2017-08-10","conditions":"Multiple Myeloma","enrollment":6},{"nctId":"NCT04045028","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma","status":"TERMINATED","sponsor":"Genentech, Inc.","startDate":"2019-07-22","conditions":"Multiple Myeloma, Non-Hodgkin Lymphoma, B-Cell Lymphoma","enrollment":41}],"_emaApprovals":[],"_faersSignals":[{"count":3,"reaction":"PYREXIA"},{"count":2,"reaction":"ASTHENIA"},{"count":2,"reaction":"DEHYDRATION"},{"count":2,"reaction":"LYMPHOPENIA"},{"count":2,"reaction":"MYALGIA"},{"count":2,"reaction":"NAUSEA"},{"count":1,"reaction":"ABDOMINAL PAIN"},{"count":1,"reaction":"DIARRHOEA"},{"count":1,"reaction":"ERUCTATION"},{"count":1,"reaction":"ERYTHEMA"}],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Darzalex"],"phase":"phase_3","status":"active","brandName":"Daratumumab/rHuPH20","genericName":"Daratumumab/rHuPH20","companyName":"Masonic Cancer Center, University of Minnesota","companyId":"masonic-cancer-center-university-of-minnesota","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Daratumumab is a monoclonal antibody that targets CD38 on multiple myeloma cells, while rHuPH20 is a recombinant human hyaluronidase that enhances subcutaneous delivery by breaking down hyaluronic acid in the extracellular matrix. Used for Multiple myeloma (subcutaneous formulation in phase 3 development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}